HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Blanchet, J.-S. Articles by Gairin, J. E. Search for Related Content PubMed PubMed Citation Articles by Blanchet, J.-S. Articles by Gairin, J. E.

A New Generation of Melan-A/MART-1 Peptides That Fulfill Both Increased Immunogenicity and High Resistance to Biodegradation: Implication for Molecular Anti-Melanoma Immunotherapy¹

Jean-Sébastien Blanchet^*, Danila Valmori, Isabelle Dufau^*, Maha Ayyoub, Christophe Nguyen^*, Philippe Guillaume, Bernard Monsarrat^*, Jean-Charles Cerottini, Pedro Romero and Jean Edouard Gairin^2,*

^* Laboratoire d’ImmunoPharmacologie Structurale, Institut de Pharmacologie et Biologie Structurale, Centre National de la Recherche Scientifique, Toulouse, France; and Ludwig Institute for Cancer Research, Division of Clinical Onco-Immunology, University Hospital and Lausanne Branch, Lausanne, Switzerland

Intense efforts of research are made for developing antitumor vaccines that stimulate T cell-mediated immunity. Tumor cells specifically express at their surfaces antigenic peptides presented by MHC class I and recognized by CTL. Tumor antigenic peptides hold promise for the development of novel cancer immunotherapies. However, peptide-based vaccines face two major limitations: the weak immunogenicity of tumor Ags and their low metabolic stability in biological fluids. These two hurdles, for which separate solutions exist, must, however, be solved simultaneously for developing improved vaccines. Unfortunately, attempts made to combine increased immunogenicity and stability of tumor Ags have failed until now. Here we report the successful design of synthetic derivatives of the human tumor Ag Melan-A/MART-1 that combine for the first time both higher immunogenicity and high peptidase resistance. A series of 36 nonnatural peptide derivatives was rationally designed on the basis of knowledge of the mechanism of degradation of Melan-A peptides in human serum and synthesized. Eight of them were efficiently protected against proteolysis and retained the antigenic properties of the parental peptide. Three of the eight analogs were twice as potent as the parental peptide in stimulating in vitro Melan-specific CTL responses in PBMC from normal donors. We isolated these CTL by tetramer-guided cell sorting and expanded them in vitro. The resulting CTL efficiently lysed tumor cells expressing Melan-A Ag. These Melan-A/MART-1 Ag derivatives should be considered as a new generation of potential immunogens in the development of molecular anti-melanoma vaccines.

This article has been cited by other articles:

				D. Michod, A. Annibaldi, S. Schaefer, C. Dapples, B. Rochat, and C. Widmann Effect of RasGAP N2 Fragment-Derived Peptide on Tumor Growth in Mice J Natl Cancer Inst, June 2, 2009; 101(11): 828 - 832. [Abstract] [Full Text] [PDF]

				L. Derre, M. Ferber, C. Touvrey, E. Devevre, V. Zoete, A. Leimgruber, P. Romero, O. Michielin, F. Levy, and D. E. Speiser A Novel Population of Human Melanoma-Specific CD8 T Cells Recognizes Melan-AMART-1 Immunodominant Nonapeptide but Not the Corresponding Decapeptide J. Immunol., December 1, 2007; 179(11): 7635 - 7645. [Abstract] [Full Text] [PDF]

				A. I. Webb, M. A. Dunstone, W. Chen, M.-I. Aguilar, Q. Chen, H. Jackson, L. Chang, L. Kjer-Nielsen, T. Beddoe, J. McCluskey, et al. Functional and Structural Characteristics of NY-ESO-1-related HLA A2-restricted Epitopes and the Design of a Novel Immunogenic Analogue J. Biol. Chem., May 28, 2004; 279(22): 23438 - 23446. [Abstract] [Full Text] [PDF]